1. Sancuso [package insert], Bedminster, NJ, Kyowa Kirin, Inc.
  2. Raber-Durlacher JE, Brennan MT, Verdonck-de Leeuw IM, et al. Swallowing dysfunction in cancer patients. Support Care Cancer. 2012;20:433-443.
  3. National Cancer Institute website. Nausea and Vomiting (PDQ®) Radiation Therapy. Available at: http://www.cancer.gov/cancertopics/pdq/supportivecare
    /nausea/HealthProfessional/page9
    . Accessed on October 10, 2017.
  4. Di Lorenzo C, Youssef NN. Diagnosis and management of intestinal motility disorders. Semin Pediatr Surg. 2010;19:50-58.
  5. Keller J, Layer P. Intestinal and anorectal motility and functional disorders. Best Pract Res Clin Gastroenterol. 2009;23:407-423.
  6. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120:1453-1461.
  7. Roeder F, Nicolay NH, Nguyen T, et al. Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer. Radiat Onocol. 2014;9:191. doi:10.1186/1748-717X-9-191.
  8. National Cancer Institute website. Oral complications of chemotherapy and head/neck radiation. Available at: http://www.cancer.gov/cancertopics/pdq
    /supportivecare/oralcomplications/HealthProfessional
    . Accessed on October 10, 2017.
  9. National Cancer Institute website. Nausea and Vomiting (PDQ®) Nausea, Vomiting (Emesis), Constipation, and Bowel Obstruction in Advanced Cancer. http://www.cancer.gov/cancertopics/pdq/supportivecare/nausea
    /HealthProfessional/page7
    . Accessed on October 10, 2017.
  10. Hursti TJ, Åvall-Lundqvist E, Börjeson S, et al. Impact of tumour burden on chemotherapy-induced nausea and vomiting. Br J Cancer. 1996;74:1114-1119.
  11. Schulmeister L. Granisetron transdermal system: a new option to help prevent chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs. 2009;13:711-714.
  12. National Comprehensive Cancer Network website. NCCN Clinical Practice Guidelines in Oncology: Head and neck cancers. V.2.2017.
  13. National Comprehensive Cancer Network website. NCCN Clinical Practice Guidelines in Oncology: Breast cancer. V.2.2017.
  14. National Comprehensive Cancer Network website. NCCN Clinical Practice Guidelines in Oncology: Small cell lung cancer. V.1.2018.
  15. National Comprehensive Cancer Network website. NCCN Clinical Practice Guidelines in Oncology: Gastric cancer. V.4.2017.
  16. National Comprehensive Cancer Network website. NCCN Clinical Practice Guidelines in Oncology: Cervical cancers. V.1.2017.
  17. National Comprehensive Cancer Network website. NCCN Clinical Practice Guidelines in Oncology: Ovarian cancer: including fallopian tube cancer and primary peritoneal cancer V.3.2017.
  18. National Comprehensive Cancer Network website. NCCN Clinical Practice Guidelines in Oncology: Endometrial carcinoma. V.3.2017.
  19. National Comprehensive Cancer Network website. NCCN Clinical Practice Guidelines in Oncology: Testicular cancer. V.2.2017.
  20. National Comprehensive Cancer Network website. NCCN Clinical Practice Guidelines in Oncology: Colon cancer. V.2.2017.
  21. National Comprehensive Cancer Network website. NCCN Clinical Practice Guidelines in Oncology: Rectal cancer. V.3.2017.
  22. Cawley MM, Benson LM. Current trends in managing oral mucositis. Clin J Oncol Nurs. 2005;9(5):584-592.
  23. Lalla RV, Latortue MC, Hong CH, et al. A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer. 2010;18(8):985-992.
  24. Jensen SB, Pedersen AML, Vissink A, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer. 2010;18:1039-1060.
  25. National Comprehensive Cancer Network website. NCCN Clinical Practice Guidelines in Oncology: Esophageal cancer. V.2.2017.
  26. Keefe DM. Intestinal mucositis: mechanisms and management. Curr Opin Oncol. 2007;19:323-327.
  27. Muehlbauer PM, Thorpe D, Davis A, Drabot R, Rawlings BL, Kiker E. Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy- and radiotherapy-induced diarrhea. Clin J Oncol Nurs. 2009;13:336-341.
  28. Stacey R, Green JT. Radiation-induced small bowel disease: latest developments and clinical guidance. Ther Adv Chronic Dis. 2014;5:15-29.
  29. Ripamonti CI, Easson AM, Gerdes H. Management of malignant bowel obstruction. Eur J Cancer. 2008;44:1105-1115.
  30. National Comprehensive Cancer Network website. NCCN Clinical Practice Guidelines in Oncology: Antiemesis V.2.2017.
  31. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29:4189-4198.
  32. Mason JW, Moon TE. Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management. Cancer Manag Res. 2013;5:179-185.
  33. Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist. 2003;8:187-198.
  34. Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM; for the Sancuso Study Group. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer. 2011;19(10):1609-1617.
  35. Data on file. Kyowa Kirin, Inc.
  36. Grunberg S, Clark-Snow R, Koeller J. Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management: proceedings from a symposium at the 2008 Multinational Association of Supportive Care in Cancer (MASCC) annual meeting. Support Care Cancer. 2010;18(suppl 1):S1-S10.
  37. Howell J, Smeets J, Drenth H-J, Gill D. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract. 2009;15:223-231.
  38. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
  39. The American Cancer Society. The American Cancer Society Web Site: Chemo Brain. http://www.cancer.org/treatment/treatmentsandsideeffects
    /physicalsideeffects/chemotherapyeffects/chemo-brain
    . Accessed on October 10, 2017.
  40. Fujii H, Iihara H, Ishihara M, TakahashiT, Yoshida K, Itoh Y. Improvement of adherence to guidelines for antiemetic medication enhances emetic control in patients with colorectal cancer receiving chemotherapy of moderate emetic risk. Anticancer Res. 2013;33(12):5549-5556.